195 related articles for article (PubMed ID: 11770190)
1. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.
Gräser T; Römer T; Wiedey KD; Janaud A
Climacteric; 2001 Dec; 4(4):332-42. PubMed ID: 11770190
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.
von Schoultz B
Climacteric; 2003 Aug; 6 Suppl 2():24-32. PubMed ID: 14669841
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest for continuous combined hormone replacement therapy in postmenopausal women.
Gräser T; Koytchev R; Müller A; Oettel M
Climacteric; 2000 Jun; 3(2):109-18. PubMed ID: 11910651
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients.
Saletu B; Anderer P; Gruber D; Metka M; Huber J; Saletu-Zyhlarz GM
Maturitas; 2002 Nov; 43(3):165-81. PubMed ID: 12443834
[TBL] [Abstract][Full Text] [Related]
5. Effects of the combined hormonal replacement drug estradiol valerate/levonorgestrel on climacteric complaints, endometrium and lipid profile of peri- and postmenopausal women.
Georgiev DB; Golbs S; Goudev A
Methods Find Exp Clin Pharmacol; 2001 May; 23(4):197-202. PubMed ID: 11676228
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
[TBL] [Abstract][Full Text] [Related]
7. Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia.
Anderer P; Semlitsch HV; Saletu B; Saletu-Zyhlarz G; Gruber D; Metka M; Huber J; Gräser T; Oettel M
Psychoneuroendocrinology; 2003 Apr; 28(3):419-45. PubMed ID: 12573306
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of two dosages of a continuous combined hormone replacement regimen.
Loh FH; Chen LH; Yu SL; Jorgensen LN
Maturitas; 2002 Feb; 41(2):123-31. PubMed ID: 11836043
[TBL] [Abstract][Full Text] [Related]
9. Estradiol valerate/dienogest.
Wellington K; Perry CM
Drugs; 2002; 62(3):491-504; discussion 505-6. PubMed ID: 11827562
[TBL] [Abstract][Full Text] [Related]
10. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study.
Bruhat M; Rudolf K; Vaheri R; Kainulainen P; Timonen U; Viitanen A
Maturitas; 2001 Dec; 40(3):259-71. PubMed ID: 11731187
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
[TBL] [Abstract][Full Text] [Related]
12. The role of antiandrogens in hormone replacement therapy.
Schneider HP
Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383
[TBL] [Abstract][Full Text] [Related]
13. Effect of long-term continuous combined hormone replacement therapy with estradiol valerate and either dienogest or norethisterone acetate on mammographic density in postmenopausal women.
Georgiev DB; Manassiev NA
Medscape Womens Health; 2002; 7(4):1. PubMed ID: 12466733
[TBL] [Abstract][Full Text] [Related]
14. Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone.
Saletu-Zyhlarz G; Anderer P; Gruber G; Mandl M; Gruber D; Metka M; Huber J; Oettel M; Gräser T; Abu-Bakr MH; Grätzhofer E; Saletu B
J Sleep Res; 2003 Sep; 12(3):239-54. PubMed ID: 12941063
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
Hudita D; Posea C; Ceausu I; Rusu M
Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
[TBL] [Abstract][Full Text] [Related]
16. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Nerbrand C; Nyberg P; Nordström L; Samsioe G
Maturitas; 2002 May; 42(1):55-62. PubMed ID: 12020980
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
[TBL] [Abstract][Full Text] [Related]
18. [Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climacteric symptoms and the endometrium].
Belaisch J; Nappi C; Affinito P; De Gezelle H; Botelho M; Oliveira HM; Martinez-Oliveira J; Gonzaga F
J Gynecol Obstet Biol Reprod (Paris); 2000 Feb; 29(1):29-40. PubMed ID: 10675831
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days.
Rouskova D; Mittmann K; Schumacher U; Dietrich H; Zimmermann T
Gynecol Endocrinol; 2015 Jul; 31(7):560-4. PubMed ID: 26217921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
